Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations
- PMID: 8033152
Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations
Abstract
In breast cancer, loss of heterozygosity (LOH) on 17p is a frequent event and a likely target is the p53 gene on 17p13.1. However, several LOH mapping studies have indicated that, in some breast tumors, LOH affects only the most distal 17p markers, suggestive of a second tumor suppressor locus in 17p13.3. In order to distinguish which gene has most probably served as the target for LOH on 17p, we have screened 141 breast tumors for somatic mutations in the p53 gene in conjunction with detailed LOH mapping on the short arm of chromosome 17. A total of 32 mutations were detected in 31 tumors, 15 of which have never been reported in breast cancer before. The majority are point mutations leading to an amino acid change in the protein. In addition, we have stained a subset of 87 tumors for the p53 protein by immunohistochemistry. In 21 of these tumors (24%), nuclear staining was detected in over 25% of the tumor cells with the anti-p53 antibody DO7. A positive correlation was found between p53-positive staining and p53 mutation (P < 0.001). A strong association was observed between p53 mutation and LOH at the TP53 locus but not between p53 expression and LOH on 17p. In breast tumors without a detectable p53 mutation but with LOH on 17p, the 17p13.3 region is always involved and, in some cases, even exclusively involved. These results suggest that a second tumor suppressor gene, located distal to TP53, is targeted by LOH on 17p in some breast tumors and that a substantial number of breast tumors stabilize p53 through mechanisms other than mutation.
Similar articles
-
Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.Clin Cancer Res. 2007 Feb 1;13(3):844-50. doi: 10.1158/1078-0432.CCR-06-2085. Clin Cancer Res. 2007. PMID: 17289876
-
Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas.Cancer Res. 1992 Dec 1;52(23):6716-21. Cancer Res. 1992. PMID: 1358438
-
High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.Oncogene. 1998 Jan 8;16(1):21-6. doi: 10.1038/sj.onc.1201509. Oncogene. 1998. PMID: 9467939
-
[Chromosome arm 17p13.3: could HIC1 be the one ?].Med Sci (Paris). 2006 Jan;22(1):54-61. doi: 10.1051/medsci/200622154. Med Sci (Paris). 2006. PMID: 16386221 Review. French.
-
[Mechanisms for inactivation of tumor suppressor genes].Nihon Rinsho. 1995 Nov;53(11):2660-5. Nihon Rinsho. 1995. PMID: 8538022 Review. Japanese.
Cited by
-
Altered p53 in microdissected, metachronous, premalignant and malignant oral lesions from the same patients.Clin Mol Pathol. 1995 Oct;48(5):M269-72. doi: 10.1136/mp.48.5.m269. Clin Mol Pathol. 1995. PMID: 16696020 Free PMC article.
-
Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis.EMBO J. 2003 Sep 15;22(18):4584-96. doi: 10.1093/emboj/cdg442. EMBO J. 2003. PMID: 12970171 Free PMC article.
-
Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21.Cancer Res. 2011 Jul 1;71(13):4628-39. doi: 10.1158/0008-5472.CAN-10-2475. Epub 2011 May 12. Cancer Res. 2011. PMID: 21565979 Free PMC article.
-
Cytogenetic differences in breast cancer samples between German and Japanese patients.J Clin Pathol. 2005 Oct;58(10):1101-3. doi: 10.1136/jcp.2004.022392. J Clin Pathol. 2005. PMID: 16189159 Free PMC article.
-
Mutations in the p53 tumor suppressor gene in colorectal cancer in Taiwan.Kaohsiung J Med Sci. 2003 Apr;19(4):151-8. doi: 10.1016/S1607-551X(09)70464-4. Kaohsiung J Med Sci. 2003. PMID: 12795343 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous